Research programme: dual action cancer therapeutics - FLAG Therapeutics

Drug Profile

Research programme: dual action cancer therapeutics - FLAG Therapeutics

Alternative Names: AA/AT compounds - Duquesne/Flag; FLAG-003

Latest Information Update: 02 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Duquesne University
  • Developer Duquesne University; FLAG Therapeutics
  • Class Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Glioma

Most Recent Events

  • 16 Apr 2016 Preclinical trials in Glioma in USA (unspecified route)
  • 16 Apr 2016 Pharmacokinetics and Pharmacodynamics data from preclinical trial in Glioma presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 01 Mar 2016 FLAG 003 receives Orphan Drug status for Glioma in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top